Overview

A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)

Status:
Active, not recruiting

Trial end date:
2022-05-31

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control with dapagliflozin and metformin

Phase:

Phase 3

Details

Lead Sponsor:

LG Chem

Treatments:

Metformin